Relaxant effect of BAY 41–2272 in the rabbit isolated detrusor smooth muscle (DSM): involvement of cGMP-independent mechanisms
© Báu et al; licensee BioMed Central Ltd. 2007
Published: 25 July 2007
Overactive bladder (OAB) is described as urgency with or without incontinence, usually accompanied by frequency and nocturia. Overactive bladder reflects involuntary DSM as a consequence of enhanced cholinergic-mediated contractions and decreased b-adrenoceptor-mediated relaxations. The nitric oxide (NO)-cyclic GMP signaling pathway has been described to modulate the muscular tone, neurotransmission and blood flow in DSM, but the exact role of NO in the bladder is not completely understood. It is accepted that NO deficiency contributes to triggering OAB. The compound BAY 41–2272 has been described as a drug that directly activates the soluble guanylate cyclase leading to NO-independent cGMP accumulation. BAY 41–2272 produces potent relaxations in vascular and non-vascular smooth muscle tissues by cGMP-dependent and independent mechanisms, but no studies have been carried out with DSM.
The aim of this study was to evaluate the relaxant effect of BAY 41–2272 in the rabbit isolated bladder and the mechanisms underlying the relaxant responses.
The present study was approved by the Ethics Committee for Experimental Research of the State University of Campinas (UNICAMP). Male New Zealand White rabbits (3 kg) were anaesthetized with urethane (1 g/kg, i.v.) After exsanguination, the abdomen was opened and the bladder was removed and placed in Krebs solution. The DSM strips (2 × 4 × 10 mm) were suspended between two metal hooks and mounted in 10 ml organ baths containing with Krebs' solution at 37°C, pH 7.4, and aerated continuously with 95% O2 and 5% CO2. The development of isometric tension was registered using force transducers connected to a PowerLab 400™ data-acquisition system (ADInstruments, MA, USA). Tissue preparations were equilibrated for 1 h before the start of the experiments. Initially, DSM preparations were challenged with 80 mM KCl to confirm tissue viability. Concentration-response curves for BAY 41–2272 (0.001–10 μM) were contructed in the presence and in the absence of L-NAME (100 μM), ODQ (10 μM) or sildenafil (0.1 μM) The relaxations were plotted as percentages of the contraction induced by carbachol (10 μM). Concentration-response curves to sodium nitroprusside (SNP, 0.01–10 μM) and gliceryl trinitate (GTN, 0.01–10 μM) were also constructed.
The potency of BAY 41–2272 was not significantly altered in the presence of L-NAME (6.37 ± 0.33), ODQ (6.66 ± 0.15) or sildenafil (6.67 ± 0.20) in comparison with vehicle (6.72 ± 0.12). Similarly the Emaxvalues were not altered in the presence of L-NAME (153.30 ± 9.02), ODQ (125.69 ± 7.06) and sildenafil (126.18 ± 5.14) compared with vehicle (134.97 ± 4.84) (Fig. 1b).
In contrast with NO donors, BAY 41–2272 causes a complete relaxation of rabbit DSM. Our findings that relaxant responses to BAY 41–2272 are unaltered by L-NAME, ODQ and sildenafil indicate that BAY 41–2272 acts in an cGMP-independent manner to produce DSM relaxations. Therefore, BAY 41–2272 constitutes a drug with great potential to treat overactive bladder.
This article is published under license to BioMed Central Ltd.